Paternal Valproate Use Not Linked to Offspring Developmental Disorders
⚠️ Pregnancy-related topic: medication, diet, and testing decisions must be made with your obstetrician and neurology team.
Source: Journal of neurology, neurosurgery, and psychiatry
Summary
Researchers studied the potential risks of neurodevelopmental disorders (NDDs) in children whose fathers used a medication called valproate during the time they were producing sperm. This study looked at data from Sweden and Norway, focusing on all live births from 2007 to 2020. The researchers compared children whose fathers took valproate to those whose fathers took other epilepsy medications, specifically lamotrigine or levetiracetam.
The key finding of the study was that there was no significant increase in the risk of NDDs in children whose fathers used valproate compared to those whose fathers used the other medications. This included conditions like autism spectrum disorder, attention-deficit/hyperactivity disorder, and intellectual disabilities. The results were consistent even when considering different doses of the medication and when focusing specifically on fathers with epilepsy.
These findings are important because they suggest that the current concerns about paternal valproate use may need to be reconsidered, especially since the study did not find a link to increased risks of NDDs. However, it is essential to note that this study has limitations, such as not being able to account for all possible factors that might affect child development. Further research may be needed to confirm these results and provide clearer guidance for families.
Free: Seizure First Aid Quick Guide (PDF)
Plus one plain-language weekly digest of new epilepsy research.
Unsubscribe anytime. No medical advice.
